Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 4/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194353 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL2196547 | 0.86 | FKBP1A (0.34) | FKBP1A | |
| SCHEMBL10299784 | 0.84 | CHRM2 (0.40) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL16249774 | 0.84 | CHRM2 (0.40) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL2199765 | 0.82 | CHRM2 (0.49) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL2199763 | 0.82 | CHRM2 (0.49) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL2197514 | 0.76 | CHRM2 (0.35) | CHRM2CHRM1CHRM3PREPFKBP1A | |
| SCHEMBL2197509 | 0.76 | CHRM2 (0.35) | CHRM2CHRM1CHRM3PREPFKBP1A | |
| SCHEMBL1446373 | 0.75 | ALDH1A1 (0.39) | CHRM2CHRM1CHRM3FKBP1AALDH1A1 | |
| SCHEMBL1446375 | 0.75 | ALDH1A1 (0.39) | CHRM2CHRM1CHRM3FKBP1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152713-B1 | PYRAZOLOPYRROLIDINES AS INHIBITORS OF GAMMA SECRETASE | ELAN PHARM INC (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7977368-B2 | Pyrazolopyrrolidines as inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20090099235-A1 | Pyrazolopyrrolidines as Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099235-A1 | Pyrazolopyrrolidines as Inhibitors of Gamma Secretase | BACE1, BACE2, APP | CHRM2 30/4885CHRM1 36/4885CHRM3 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.